You are here

Commercialization of a Novel Therapeutic for Alzheimer's Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AG044187-02A1
Agency Tracking Number: R42AG044187
Amount: $1,059,937.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA16-092
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-30
Award End Date (Contract End Date): 2020-05-31
Small Business Information
Louisville, KY 40243-1805
United States
DUNS: 841834083
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (859) 257-1412
Business Contact
Phone: (859) 257-1412
Research Institution
LEXINGTON, KY 40526-0001
United States

 Nonprofit College or University

Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s
diseaseADare becoming increasingly expensive and in many cases disappointingly
unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small
moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production of Ain mouse
models of AD pathology through Elkmediated transcriptional repression of presenilinbut
not presenilinAlthough our preliminary data show BNCeffectively modulatesof the main
pathologic features of AD without the adverse effects associated with current monotherapeuticsthere is a need for characterization of its basic pharmacology toxicity and for
identification of the most efficacious treatment regimen in a well characterized mouse model of
Adeposition and neuroinflammationX FAD miceIf successfulthe data obtained in this
proposal will provide necessary pharmacology safety toxicology data to de risk the drug for
potential corporate partners thus increasing the likelihood of successful commercialization

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government